Scarica l'app Stockscreener
11.29
1.35%
-0.155
Dopo l'orario di chiusura:
11.29
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Precedente Chiudi:
$11.45
Aprire:
$11.4
Volume 24 ore:
422.38K
Relative Volume:
0.33
Capitalizzazione di mercato:
$464.23M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-2.2008
EPS:
-5.13
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
-0.53%
1M Prestazione:
+3.53%
6M Prestazione:
-80.00%
1 anno Prestazione:
-82.96%
Intervallo 1D:
$11.12
$11.46
Intervallo di 1 settimana:
$11.12
$11.63
Portata 52W:
$9.775
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Nome
Keros Therapeutics Inc
Settore
Industria
Telefono
617-314-6297
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Confronta KROS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.29 | 464.23M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
509.04 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.14 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
605.52 | 36.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
280.96 | 36.37B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.47 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-12-16 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-16 | Reiterato | Oppenheimer | Outperform |
| 2024-12-13 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-12 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-12-12 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Iniziato | Jefferies | Buy |
| 2024-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-23 | Iniziato | Guggenheim | Buy |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-02-21 | Iniziato | William Blair | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-07-31 | Iniziato | Wedbush | Outperform |
| 2023-07-26 | Iniziato | BofA Securities | Buy |
| 2023-02-14 | Iniziato | Cowen | Outperform |
| 2022-10-18 | Iniziato | Truist | Buy |
| 2022-07-26 | Iniziato | BTIG Research | Buy |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2020-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
Emerald Advisers LLC Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
(KROS) Investment Report - Stock Traders Daily
ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Keros Therapeutics (NASDAQ:KROS) Financial Analysis - Defense World
29,146 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Connor Clark & Lunn Investment Management Ltd. - Defense World
Bank of New York Mellon Corp Raises Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet - Yahoo Finance
AlphaQuest LLC Purchases 2,964 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
(KROS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine (NASDAQ:KROS) - Seeking Alpha
Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade - MSN
Equities Analysts Set Expectations for KROS Q1 Earnings - MarketBeat
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $42.33 - MarketBeat
FY2026 Earnings Estimate for KROS Issued By Leerink Partnrs - MarketBeat
HC Wainwright Issues Optimistic Outlook for KROS Earnings - MarketBeat
Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $42.33 - Defense World
Leerink Partnrs Has Bullish Outlook for KROS FY2026 Earnings - Defense World
Handelsbanken Fonder AB Boosts Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
HC Wainwright Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price - MarketBeat
Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $26.00 - MarketBeat
(KROS) On The My Stocks Page - Stock Traders Daily
Q1 EPS Forecast for Keros Therapeutics Lifted by Analyst - Defense World
What is William Blair’s Forecast for KROS Q1 Earnings? - Defense World
Keros Therapeutics (NASDAQ:KROS) Releases Earnings Results, Beats Expectations By $0.22 EPS - MarketBeat
Y Intercept Hong Kong Ltd Raises Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Q2 Earnings Estimate for KROS Issued By Leerink Partnrs - MarketBeat
Keros Therapeutics CEO to Speak at Major Conferences - TipRanks
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - The Manila Times
When and Where to Hear Keros Therapeutics' Latest Updates: CEO's March Conference Schedule - StockTitan
Keros Therapeutics Hold Rating: Uncertainty in KER-065 Development and Cibotercept Safety Concerns - TipRanks
Keros Therapeutics stock target cut to $40 at H.C. Wainwright By Investing.com - Investing.com South Africa
Analyst Expectations For Keros Therapeutics's Future - Benzinga
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect - ACCESS Newswire
Keros Therapeutics Strengthens Financial Position Amid R&D Expansion - TipRanks
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - MSN
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Keros Therapeutics, Inc. SEC 10-K Report - TradingView
Keros Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Keros Therapeutics reports Q4 EPS ($1.14) vs. ($1.34) last year - TipRanks
How Keros Therapeutics Secured Funding Until 2029 Despite Widening Losses - StockTitan
Keros Therapeutics Inc Azioni (KROS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):